FR-194921 is a new potent, selective, and orally bioavailable antagonist for central adenosine A1 receptors. FR194921 showed potent and selective affinity for the adenosine A1 receptor without affinity for A2A and A3 receptors and did not show any species differences in binding affinity profile among human, rat, and mouse. FR194921 exerts both cognitive-enhancing and anxiolytic activity, suggesting the therapeutic potential of this compound for dementia and anxiety disorders. References: Matsuya T, Takamatsu H, Murakami Y, Noda A, Ichise R, Awaga Y, Nishimura S. Synthesis and evaluation of [11C]FR194921 as a nonxanthine-type PET tracer for adenosine A1 receptors in the brain. Nucl Med Biol. 2005 Nov;32(8):837-44. PubMed PMID: 16253808.

纯度：≥98%

CAS：202646-80-8